Skip to main content
    E

    Entera Bio Ltd (ENTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    -0.09 (-2.89%)

    Market Cap: $541.57M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Entera Bio Ltd (ENTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Entera Bio reported revenue of $42.00K for the fiscal year ended Dec 31, 2025, down 76.8% from the year before. That year, net income was -$11.44M with a net margin of -27235.7%, operating cash flow was -$7.37M and free cash flow was -$7.48M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$15.60M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue fell from $500.00K, a compound annual decline of 29.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$42.00K-76.8%0.0%-27450.0%-27235.7%
    Dec 2024$181.00KN/A5.0%-5295.6%-5271.3%
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$134.00K-76.5%24.6%-9714.2%-9754.5%
    Dec 2021$571.00K+56.4%34.7%-2139.6%-2134.3%
    Dec 2020$365.00K+54.7%17.8%-3059.7%-3072.9%
    Dec 2019$236.00K-52.8%11.0%-4853.4%-4574.2%
    Dec 2018$500.00KN/A100.0%-2172.2%-2060.8%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$42.00K$181.00K$0$134.00K$571.00K$365.00K$236.00K$500.00K$0$0
    Cost of revenue$42.00K$172.00K$0$101.00K$373.00K$300.00K$210.00K$0$0$0
    Gross profit$0$9.00K$0$33.00K$198.00K$65.00K$26.00K$500.00K$0$0
    Research and development$6.00M$4.50M$4.51M$5.85M$6.77M$6.38M$7.20M$8.52M$2.77M$2.65M
    Operating income-$11.53M-$9.59M-$8.89M-$13.02M-$12.22M-$11.17M-$11.45M-$10.86M-$11.34M-$5.37M
    Net income-$11.44M-$9.54M-$8.89M-$13.07M-$12.19M-$11.22M-$10.79M-$10.30M-$11.20M-$1.20M
    EBITDA-$11.41M-$9.48M-$8.80M-$12.87M-$12.19M-$11.13M-$11.30M-$10.77MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$42.00K$82.00K$42.00K$57.00K$0$4.48M
    Gross profit$0$0$0-$7.00K$0$0$0$0$0$9.00K$0-$13.00K
    Operating income-$7.26M-$4.56M-$3.54M-$3.04M-$3.26M-$2.67M-$2.56M-$2.34M-$3.02M-$2.17M-$2.06M-$1.96M
    Net income-$15.60M-$7.31M-$3.50M-$3.02M-$3.20M-$2.66M-$2.57M-$2.36M-$3.02M-$2.15M-$2.02M-$2.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $623.00K by $6.49M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$15.99M$9.39M$11.77M$13.13M$25.99M$9.72M$16.70M$13.34M$13.28M$6.29M
    Current assets$15.30M$8.97M$11.26M$12.85M$25.33M$9.11M$15.64M$12.47M$12.42M$5.43M
    Cash and equivalents$7.11M$8.66M$11.02M$12.31M$24.89M$8.59M$15.19M$7.51M$11.75M$4.16M
    Total liabilities$2.89M$1.31M$1.38M$1.37M$3.42M$2.21M$4.78M$3.23M$44.84M$31.53M
    Short-term debt$230.00K$170.00K$134.00K$91.00K$179.00K$189.00K$177.00KN/A$37.35M$9.88M
    Long-term debt$393.00KN/AN/AN/AN/AN/AN/AN/A$3.89M$4.83M
    Shareholder equity$13.10M$8.08M$10.39M$11.75M$22.57M$7.51M$11.92M$10.12M-$34.45M-$25.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$277.04M$19.48M$13.13M$15.99M$17.41M$19.67M$21.60M$9.39M$7.74M$10.04M$10.24M$11.77M
    Total liabilities$2.76M$12.21M$2.44M$2.89M$2.17M$2.41M$2.22M$1.31M$1.29M$1.50M$1.38M$1.38M
    Cash and equivalents$265.88M$11.31M$4.14M$7.11M$8.57M$10.86M$12.57M$8.66M$6.92M$9.06M$9.19M$11.02M
    Shareholder equity$274.28M$7.27M$10.69M$13.10M$15.23M$17.26M$19.38M$8.08M$6.45M$8.53M$8.86M$10.39M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$7.37M-$6.82M-$7.31M-$12.50M-$9.06M-$10.56M-$4.97M-$13.76M-$4.38M-$4.22M
    Capital expenditures$107.00K$3.00K$17.00K$47.00K$17.00K$53.00K$40.00K$68.00K$51.00K$41.00K
    Free cash flow-$7.48M-$6.82M-$7.33M-$12.55M-$9.08M-$10.61M-$5.01M-$13.83M-$4.43M-$4.26M
    Investing cash flow-$107.00K-$3.00K-$17.00K-$102.00K-$17.00K-$53.00K-$40.00K-$68.00K-$51.00K-$41.00K
    Financing cash flow$13.71M$4.48M$6.04M$13.00K$25.38M$4.05M$12.65M$9.62M$11.11M$7.22M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.40M-$3.46M-$3.09M-$1.83M-$2.50M-$1.63M-$1.40M-$1.47M-$2.15M-$1.33M-$1.86M-$2.62M
    Capital expenditures$21.00K$3.00K$0$27.00K$43.00K$29.00K$8.00K$3.00K$1$4$0$5.00K
    Free cash flow-$7.42M-$3.47M-$3.09M-$1.86M-$2.54M-$1.66M-$1.41M-$1.47M-$2.15M-$1.34M-$1.86M-$2.62M
    Last 12 quarters

    Frequently Asked Questions About ENTX

    What is Entera Bio's annual revenue?

    Entera Bio reported revenue of $42.00K for the fiscal year ended Dec 31, 2025.

    How fast is Entera Bio's revenue growing?

    Revenue was down 76.8% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Entera Bio profitable?

    No. Entera Bio reported net income of -$11.44M for the fiscal year ended Dec 31, 2025, with a net margin of -27235.7%.

    How much free cash flow does ENTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.37M minus capital expenditures of $107.00K produced free cash flow of -$7.48M.

    How much debt does Entera Bio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $393.00K, short-term debt of $230.00K and cash and equivalents of $7.11M.